OncoMatch/Clinical Trials/NCT06251388
A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer
Is NCT06251388 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies AK104 for cervical cancer.
Treatment: AK104 — This study will evaluate the efficacy and safety of concurrent chemoradiotherapy（CCRT）followed by cadonilimab（AK104) in high risk local advanced cervical cancer. Participants received CCRT，efficacy evaluation of CCRT was no disease progression who maintained with AK104（10.0 mg/kg，Q3W）until drug exposure over 1 years or disease progression or intolerable toxicity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage III, IVA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Pior not received systemic therapy before CCRT, Including but not limited to radiotherapy, chemotherapy, immunotherapy, and biological therapy,etc.
Cannot have received: antitumor therapy
Has received other antitumor therapy before CCRT
Cannot have received: immune checkpoint inhibitor
Previously received immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, and Ox40 . etc.), immune cell therapy. etc. Any tumor immune mechanisms treatment
Cannot have received: allogeneic stem cell or parenchymal organ transplantation
Previously received allogeneic stem cell or parenchymal organ transplantation
Lab requirements
Blood counts
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.
Kidney function
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.
Liver function
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.
Adequate organ function, evidenced by the following laboratory results within 7 days prior to the study treatment.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify